The classic triad of obstructive symptoms, systemic embolization, and constitutional symptoms occur in conjunction infrequently. However, one of the three attributes may signify this entity on its own [
6]. Obstructive symptoms of blood flow occur in 54 to 95% of patients in a valvular “ball-valve” mechanism [
6]. This predominantly entails cardiac failure, accounting for 43% of cases in one series of studies, with dyspnea and lower extremity edema as predominant symptoms [
6]. Systemic embolization occurs in 10 to 45% of patients with myxoma, with roughly two-thirds occurring in the central nervous system [
6]. The literature documents cases of embolization to the extremities, aortic saddle, coronary arteries, kidneys, liver, spleen, and eye [
3‐
5]. Constitutional symptoms occur in 90% of cases [
3‐
6]. These non-specific markers of disease can include myalgia, arthralgia, muscle weakness, fatigue, fever, weight loss, anemia, elevated erythrocyte sedimentation rate, leukocytosis, and thrombocytopenia [
3‐
6,
18,
20]. The presentation mimics many clinical scenarios such as syncope, collagen vascular disease, rheumatic heart disease, disseminated malignant disease, and infective endocarditis; thus, diagnosis is often made during a workup for these cardiac dysfunctions or disease processes [
4,
21]. Cardiac myxoma typically presents with obstructive symptoms, but embolization of tumor or adherent clot occurs in 30 to 40% of patients with myxoma at any location [
5,
22]. In addition, neurological symptoms due to embolism and auscultation abnormalities occur more frequently with patients of a young age [
6]. Tumors arising from the mitral valve more often present with symptoms of embolization [
7,
19]. The higher risk of embolization has been attributed to motion of the valve leaflets and the high pressure of the left ventricle [
18,
19]. This may explain why patients present at younger ages and have few constitutional symptoms, as even small tumors can initiate embolic events.